TQB3911 not checked
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “TQB3911 is a small molecule BCR::ABL1 allosteric inhibitor. By occupying the myristyl binding site, TQB3911 recovers the inhibition of BCR::ABL1 fusion protein kinase activity, and ultimately inhibits the proliferation of tumor cells.”In the company’s words, NCT06672263 on ClinicalTrials.gov
- Tested for
- Chronic Myelogenous Leukemia
- Main trialPhase 1
- “Phase I clinical trial to explore the safety, tolerability, and initial efficacy of TQB3911 tablets in BCR::ABL fusion gene positive leukemia.”In the company’s words, NCT06672263 on ClinicalTrials.gov
Other drugs for Chronic Myelogenous Leukemia
- OlverembatinibAscentage Pharma Group Inc. · Phase 3
- Radotinib HClIl-Yang Pharm. Co., Ltd. · Phase 3
- ELVN-001Enliven Therapeutics · Phase 3
- HS-10382Hansoh · Phase 3
- TGRX-678TargetRx · Phase 3
- PonatinibTakeda · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Not yet recruiting | Sep 2026 | A Clinical Trial to Evaluate the Safety and Tolerability of TQB3911 Tablets in Patients With BCR::ABL Fusion Gene Positive Leukemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026